DexCom (NASDAQ:DXCM) EVP Sells $226,669.05 in Stock

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the transaction, the executive vice president directly owned 126,043 shares in the company, valued at approximately $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DexCom stock opened at $90.82 on Monday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $34.27 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41. The company has a 50 day moving average of $79.21 and a 200-day moving average of $71.61. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

Get DexCom alerts:

DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the business earned $0.48 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Wall Street Zen cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Argus boosted their target price on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Finally, UBS Group set a $96.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Check Out Our Latest Stock Analysis on DXCM

Hedge Funds Weigh In On DexCom

Hedge funds have recently modified their holdings of the business. Reflection Asset Management bought a new position in DexCom during the 4th quarter worth $25,000. Ascentis Independent Advisors acquired a new position in DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $32,000. Wellington Grp LLC grew its position in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Featured Stories

• Five stocks we like better than DexCom
• Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
• Rubrik’s AI Security Bet Could Power the Next Leg Higher
• Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
• Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.